TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01728311

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1082439
Description: BAY1082439 will be given orally once daily with a 21 days cycle. Dose will be started from 15mg.
Study: NCT02755753

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rebamipide
Description: Oral administration of Mucosta (rebamipide) 100 mg, 1 tablet, PO, tid, 30 minutes before breakfast, lunch, and dinner

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rebamipide-placebo
Description: Oral administration of Mucosta®-placebo, 1 tablet, PO, tid, 30 minutes before breakfast, lunch and dinner
Study: NCT03795129

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SleepLife Application w/FitBit
Description: Subjects receive a FitBit. Subjects receive access to the SleepLife Application. Subjects receive training and assistance setting up use and access to the SleepLife Application.~Subjects' physicians will receive subject sleep data. Subjects and physicians have the option of messaging each other through the SleepLife application.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: FitBit w/Minimal to No SleepLife App.
Description: Subjects will receive a FitBit. Subjects will be told about the SleepLife Application (but not be shown how to access it).~Subjects will receive no training with regard to how to access SleepLife Application.~Subjects' physicians will receive no subject sleep data.
Study: NCT02112708

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rational-Emotive-Behavioral Therapy
Description: A social worker held eight 30 minutes sessions fortnightly. First session is informative about the type of treatment to be performed. The next sessions work events, thoughts and feelings with the goal of changing the dysfunctional thoughts by other more rational ones, measured by scales.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Group usual care
Description: In the control group the dysthymia is treated as usual with the conventional treatment.
Study: NCT04184843

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: iWalk Toolkit
Description: Intervention period: 5 months~Intervention:~1. A toolkit consisting of 3 components: an educational guide, a smartphone app, and an educational video.~2. Access to a clinical expert by email or phone
Study: NCT04013087

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oral feeding of Feihe Stage 1 infant formula
Description: Oral feeding of Feihe Stage 1 infant formula for 16 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Oral feeding of control Stage 1 formula
Description: Oral feeding of control Stage 1 formula for 16 weeks (A commercially available product with comparable composition but does not contain sn-2 palmitate enriched vegetable oil as an ingredient (regular vegetable oil is used))

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Breast feeding
Description: Breast feeding of human milk for 16 weeks
Study: NCT02739555

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Thermal destruction with radiofrequency or laser

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acide Zoledronique
Study: NCT01253070

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration
Description: Undergo bone marrow aspirate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daunorubicin Hydrochloride
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib Tosylate
Description: Given PO
Study: NCT03654521

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Fetal interventricular septum thickness
Description: Two-dimensional ultrasound fetal cardiac imaging test

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Fetal interventricular septum thickness
Description: Two-dimensional ultrasound fetal cardiac imaging test
Study: NCT03767140

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: acupuncture
Description: The patients were randomized in two groups, one verum acupuncture, submitted to real acupuncture treatment, and the other sham acupuncture, treated with false acupuncture

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: acupuncture
Description: The patients were randomized in two groups, one verum acupuncture, submitted to real acupuncture treatment, and the other sham acupuncture, treated with false acupuncture
Study: NCT01974401

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: supragingival irrigators containing chlorhexidine
Description: patients received irrigation by oxyjet supra gingival irrigators containing chlorhexidine for at least 3 minutes for all dentulous regions of jaws which was performed by researchers once daily.
Study: NCT03694132

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: functional MRI
Description: conditioning brain activity with peripheral stimulations

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: structural MRI
Description: diffusion MRI and tractography for evaluating the brain structures

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EEG/MEG
Description: conditioning brain activity with peripheral stimulations
Study: NCT01242800

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: palliative surgery
Description: Undergo standard palliative surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Description: Undergo early surgery
Study: NCT02791256

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2a
Study: NCT02104440

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sequential infusion of allogeneic mesenchymal stem cells expanded in vitro
Study: NCT04267497

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amphotericin B Liposomal 50 MG
Description: Amphotericin B 50 mg powder for infusion diluted in 12 ml of sterile water. It will be administered by nebulized route 25 mg (6 ml), 3 times a week, for 6 weeks.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sterile water for injection. It will be administered by nebulized route: 6 ml, 3 times a week for 6 weeks.
Study: NCT00716612

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Coenzyme Q 10
Description: PO Coenzyme Q 10 120 mg QD

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo control
Description: po Placebo QD
Study: NCT02064036

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Radiosurgical Boost
Description: Intensity Modulated Radiotherapy (IMRT)2 with Concurrent Androgen Blockade to Whole Pelvis, Prostate, and Seminal Vesicles Followed by: Stereotactic Radiosurgical Boost3 to the Prostate with Implanted Electromagnetic Transponder Beacon Intrafraction Guidance

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Casodex
Description: Neoadjuvant Androgen Blockade before radiation therapy and Adjuvant Androgen Blockade after radiation therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprolide
Description: Neoadjuvant Androgen Blockade before radiation therapy and Adjuvant Androgen Blockade after radiation therapy
Study: NCT03665337

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mTranS-C
Description: MOBILE HEALTH

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: MOBILE HEALTH
Study: NCT03244488

Intervention type: DRUG
Intervention: Scopolamine Injectable Product
Description: 2.5 or 5 mcg/kg of scopolamine via IV

Intervention type: DRUG
Intervention: Scopolamine Injectable Product
Description: 2.5 or 5 mcg/kg of scopolamine via IV

Intervention type: DRUG
Intervention: Mecamylamine Pill
Description: 10 or 20mg of mecamylamine orally

Intervention type: DRUG
Intervention: Mecamylamine Pill
Description: 10 or 20mg of mecamylamine orally
Study: NCT04998708

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Relaxation technique
Description: The intervention group performed two types of relaxation techniques, that have shown their positive effects on immune functions, including progressive muscle relaxation exercise (PMRs)16 and cognitive-behavioral stress management (CBSM)32. We used two types of relaxation techniques to produce maximum effects of relaxation techniques within the limited period of COVID-19 quarantine (2 weeks). the control groups did not receive any treatment during the study; however, they were treated afterwards.
Study: NCT03060473

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: Azithromycin 1 gm PO once

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Erythromycin
Description: Erythromycin 250 mg IV every 6 hours for 48 hours followed by 500 mg PO every 8 hours for 5 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ampicillin
Description: Ampicillin 2 gm IV every 6 hours for 2 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ampicillin
Description: Ampicillin 2 gm IV every 6 hours for 2 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Description: Amoxicillin 500 mg PO every 8 hours for 5 days (Azithromycin ARM) Amoxicillin 250 mg PO every 8 hours for 5 days (Erythromycin ARM)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin
Description: Amoxicillin 500 mg PO every 8 hours for 5 days (Azithromycin ARM) Amoxicillin 250 mg PO every 8 hours for 5 days (Erythromycin ARM)
Study: NCT03108482

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Co-crystal E-58425 (Tramadol/Celecoxib)
Description: Co-crystal E-58425 (Tramadol/Celecoxib): Two immediate release oral over-encapsulated tablets of 100 mg, every 12 hours for 48 hours.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tramadol (Ultram®)
Description: Tramadol: One immediate release oral over-encapsulated tablet of 50 mg, every 6 hours for 48 hours.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Celecoxib (Celebrex®)
Description: Celecoxib: One immediate release oral over-encapsulated capsule of 100 mg, every 12 hours for 48 hours.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 100 mg or 200 mg oral over-encapsulated tablets every 6 hours for 48 hours.
Study: NCT00733967

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Varenicline
Description: Varenicline (oral capsule): 0.5 mg once daily for 3 days; 0.5 mg twice daily for 2 days; 1 mg twice daily for one day; 1 mg once daily for one day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching oral placebo capsules as control.
Study: NCT04447716

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Given PO

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab and Hyaluronidase Human
Description: Given SC
Study: NCT04212117

Intervention type: OTHER
Group type: OTHER
Intervention: The Patient Activated Learning System (PALS)
Description: Randomization into PALS arm.

Intervention type: OTHER
Group type: OTHER
Intervention: WebMD
Description: Randomization into WebMD arm.
Study: NCT02130999

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tasimelteon 20 mg capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tasimelteon 20 mg capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tasimelteon 2 mg I.V.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tasimelteon 2 mg I.V.
Study: NCT00906126

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Misoprostol
Description: Oral misoprostol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Misoprostol
Description: Oral misoprostol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Misoprostol
Description: Oral misoprostol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Misoprostol
Description: Oral misoprostol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Misoprostol
Description: Oral misoprostol
Study: NCT04326257

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab+Relatlimab
Description: IV administration of both Nivolumab and Relatlimab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab+Ipilimumab
Description: IV administration of both Nivolumab and Ipilimumab
Study: NCT00000948

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aldesleukin
Description: Il-2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ART
Description: antiretroviral therapy for the treatment of HIV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ART
Description: antiretroviral therapy for the treatment of HIV
Study: NCT06360861

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogenic placenta derived mesenchymal stem cells
Description: Allogenic placenta derived mesenchymal stem cells, 3 million cells/kg body weight via intravenous injection.
Study: NCT03635918

Intervention type: DEVICE
Group type: OTHER
Intervention: NightOwl HSAT
Description: Patient wears the NightOwl sensor device
Study: NCT04550117

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Insertion of Intraspinal pressure monitor
Description: A fiberoptic pressure monitoring wire will be placed into the subarachnoid space at the site of traumatic spinal cord injury
Study: NCT04905043

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acalabrutinib
Description: Participants will receive a single oral dose of acalabrutinib 100 mg capsule on Day 1 (Period 1) and Day 4 (Period 2).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SmartPill®
Description: Participnats will receive a single oral dose of wireless motility/pH capsule (SmartPill®) on Day 1 (Period 1) and Day 4 (Period 2).
Study: NCT04896216

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stigma Reduction Intervention
Description: Care providers will complete the Stigma Reduction Intervention curriculum. This study uses a modified Zelen design. Control arm participants will be aware that they are part of an observational study but not that they are in the control arm of an intervention study. This avoids artificially inducing changes to the standards of medical care in facilities randomization to the control arm, a common consequence in RCTs to evaluate population based services.
Study: NCT03485586

Intervention type: DEVICE
Intervention: Traditional ultrasound biometrics
Description: To evaluate the clinical feasibility of using a new optical coherence interferometry ( lenstar ),comparing with traditional ultrasonic biometry and keratometry in the accuracy and characteristics for intraocular lens calculation of cataract after PPV
Study: NCT01242800

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: palliative radiation therapy
Description: Undergo standard palliative radiotherapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Undergo radiotherapy
Study: NCT03485586

Intervention type: DEVICE
Intervention: Lenstar
Description: To evaluate the clinical feasibility of using a new optical coherence interferometry ( lenstar ),comparing with traditional ultrasonic biometry and keratometry in the accuracy and characteristics for intraocular lens calculation of cataract after PPV
Study: NCT02097498

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Directed feedback
Description: Group will receive feedback from an airway management expert while the paramedic review their baseline simulation scenario through recorded video

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Basic Videolaryngoscopy Videos
Description: Group will watch a series of educational videos related to common airway management errors.
Study: NCT04395872

Intervention type: BEHAVIORAL
Intervention: Psychiatric counseling
Description: Patients who are admitted to the COVID-19 care unit of the Catholic University of Daegu Hospital are subject to consultation with the psychiatrist. By retrospectively reviewing the medical records of the request and the results of the subjects, We collected Socio-demographic information, medical severity (oxygen saturation, chest x-ray readings, medication being administered), clinical psychological scale (PHQ-9, GAD-7, PC-PTSD-5, AIS, P4, SF-36, SCL-90-R) This study evaluates whether there is a difference in psychological scale according to differences in socio-demographic status and medical severity, and compares psychological psychological measures before and after referral to mental health medicine to evaluate the effectiveness of psychiatric counseling.
Study: NCT00223717

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clonidine
Description: 0.1-0.2mg po. Single dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitroglycerin transdermal
Description: 0.05-0.2 mg patch. 1 application. Alone or in combination with DDAVP.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dipyridamole/ Aspirin (Aggrenox)
Description: dipyridamole 200 mg and aspirin 25 mg po. Single dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desmopressin (DDAVP)
Description: 0.2 - 0.6mg po. Single dose. Alone or in combination with nitroglycerin transdermal or nifedipine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil
Description: 25- 100 mg po. Single dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nifedipine
Description: 10-30 mg po. Single dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydralazine
Description: 10-50 mg po. Single dose
Study: NCT02177500

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan + hydrochlorothiazide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT03336125

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: Vitamin D (40µg/day) will be compared with placebo

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 120 mg olive oil
Study: NCT03096535

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cooling
Description: Individualized cooling protocol.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thermoneutral
Description: Thermoneutral control day.
Study: NCT00223717

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide
Description: 12.5-100 mg po. Single dose.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Po or patch. Single dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bosentan
Description: 62.5 -125 mg po. Single dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diltiazem
Description: 30-60 mg po. Single dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eplerenone
Description: 50-100 mg po. Single dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: guanfacine
Description: 1-3 mg po. Single dose.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: L-arginine
Description: 6-17 g po. Single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: captopril
Description: 25-50 mg PO. Single dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carbidopa
Description: 25-200 mg PO. Single dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: losartan
Description: 25-200 mg PO. Single dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metoprolol tartrate
Description: 25-100 mg PO. Single dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nebivolol hydrochloride
Description: 2.5-40 mg PO. Single dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prazosin hydrochloride
Description: 0.5-1 mg PO. Single dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tamsulosin hydrochloride
Description: 0.4-0.8 mg PO. Single dose.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Head-up tilt.
Description: Head of the bed elevated 10 degrees (7 inch) or whole bed tilted head-up 5 degrees in reverse trendelenburg (head of the bed elevated 7 inches)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aliskiren
Description: aliskiren (Tekturna) 150-300mg po single dose

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Local heat stress
Description: Passive heat-stress using a commercial heating pad applied over the abdomen and part of the torso
Study: NCT01526239

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Colorectal cancer screening pamphlet
Description: Colorectal cancer screening pamphlet
Study: NCT04021329

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: CBT Therapy
Description: information added previously

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: CBT Therapy
Description: information added previously
Study: NCT00953745

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Escitalopram
Description: All subjects will begin on escitalopram and placebo for 8 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aripiprazole
Description: Subjects who fail to respond to Escitalopram will continue on Escitalopram and augment with active Aripiprazole.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Capsule
Description: All subjects will begin on escitalopram and placebo capsule for 8 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Tablet
Description: After 8 weeks, subjects will be given a 2 week supply of escitalopram and placebo tablet.
Study: NCT03384277

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Steroid
Description: Methylprednisolone 0.8 mg/kg/day (or equivalent corticosteroid doses) for 3 weeks（then tapering gradually, 8 weeks in total）

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Steroid
Description: Methylprednisolone 0.8 mg/kg/day (or equivalent corticosteroid doses) for 3 weeks（then tapering gradually, 8 weeks in total）

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375mg/m2 for one dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: cyclophosphamide 2 mg/kg/day until inhibitor negative (no longer than five weeks)